Penumbra Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Penumbra Inc's ROA in the third quarter of 2026?
Penumbra Inc achieved a return on average assets (ROA) of 8.13 % in its third quarter of 2026, this is above PEN's average return on assets of 3.07%.
Penumbra Inc assets over the 12 months ending in its third quarter of 2026 are valued at $1,931 million

ROA fell compared to the second quarter of 2026, despite the net income growth of 21.45% from the second quarter of 2026.

However, within the Healthcare sector 113 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 633, from total ROA ranking in the second quarter of 2026 at 663.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	16.09 %	17.91 %	19.15 %	34.49 %	33.98 %
Y / Y Net Income Change	-7.79 %	-23.1 %	-16.93 %	40.55 %	55.28 %
Net Income (TTM) in million	157	161	171	178	164
Return On Assets (TTM)	8.13 %	8.63 %	9.58 %	10.39 %	10.3 %
PEN's Total Ranking	# 633	# 663	# 615	# 668	# 1659
Total Assets (TTM) in million	2,025	1,975	1,898	1,827	1,744
Seq. Total Assets Change	2.55 %	4.02 %	3.94 %	4.71 %	4.15 %
Seq. Net Income Change	21.45 %	6.83 %	-31.17 %	3.25 %	1.28 %

PEN's 5 Years Annual ROA >> Back to PEN Management Effectiveness >> Compare PEN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 34
Sector	# 114
Overall	# 753

Return On Assets Statistics
High	Average	Low
10.39 %	3.07 %	-2.5 %
(Dec 31 2025)		(Dec 31 2020)

Financial Statements
Penumbra Inc's Assets	$ 2,025 million	PEN's Balance sheet
Penumbra Inc's Income	$ 42 million	Quarterly PEN's Income Statement
PEN's Income by Division		See PEN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	34.49 %	-0.83 %	16.16 %	5.7 %	42.47 %
Total Assets in million	1,827	1,358	1,369	1,179	1,115
Y / Y Net Income Change	1168.11 %	-84.59 %	-	-	-
Net Income in million	178	14	91	-2	3
Annual Return On Assets	9.73 %	1.03 %	6.64 %	-0.17 %	0.24 %

PEN's 5 Years Annual ROA >> Back to PEN Management Effectiveness >> Compare PEN ROA to its Competitors

Comment on PEN's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 9.73 % compared to prior year, due to annual net income growth of 1168.11 % to $177.69 million, while value of Penumbra Inc's overall assets grew just by 34.49 % to $1,826.52 million, compared to $1,826.52 a year before.

More Return On Assets Ratios
PEN's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PEN's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PEN's Competitors
Subscribers only: Roa for Penumbra Inc's Suppliers
Subscribers only: Return On Assets for PEN's Customers

You may also want to know
PEN's Roi	PEN's Inventory Turnover Ratio	PEN's Growth Rates	PEN's Dividend Comparisons
	PEN's Profitability Ratios	PEN's Asset Turnover Ratio	PEN's Dividend Growth
PEN's Roe	PEN's Valuation Ratios	PEN's Financial Strength Ratios	PEN's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %
Hca Healthcare Inc	11.73 %
Carlisle Companies Incorporated	11.72 %
Regeneron Pharmaceuticals Inc	11.50 %
Lantheus Holdings Inc	11.43 %
Msa Safety Inc	11.01 %
Encompass Health Corporation	10.99 %
Inspire Medical Systems inc	10.89 %
Transmedics Group Inc	10.67 %
Bristol myers Squibb Company	10.47 %

Date modified: 2026-10-30T13:20:27+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.